IRLAB reports positive results from the second part of a Phase I study with IRL757

Gothenburg, Sweden, May 28, 2025 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company that discovers and develops new treatments for Parkinson’s disease, today announces the company has successfully completed the second and final part of its clinical Phase I study, in which the drug candidate IRL757, being developed for the treatment of apathy, was administered in multiple ascending doses (MAD). The results show that IRL757 is well absorbed and provides good exposure in the body following ten days of dosing. All participants completed the study, and no serious adverse events were recorded. The safety, tolerability and pharmacokinetic profile of IRL757 support continued clinical development.

IRLAB to Present at BioStock Global Forum 2025

IRLAB is granted a patent expanding the patent protection for the drug candidate mesdopetam in the US